Ly6Chi Monocytes Direct Alternatively Activated Profibrotic Macrophage Regulation of Lung Fibrosis
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a devastating disease. Antiinflammatory therapies, including corticosteroids, are of no benefit. The role of monocytes and macrophages is therefore controversial. Objectives: To define the role of monocytes and macrophages during lung fibrogenesis and resolution, and explore the phenotype of the cells involved. Methods: We used multiple in vivo depletional strategies, backed up by adoptive transfer techniques. Further studies were performed on samples from patients with IPF. Measurements and Main Results: Depletion of lung macrophages during fibrogenesis reduced pulmonary fibrosis as measured by lung collagen (P = 0.0079); fibrosis score (P = 0.0051); and quantitative polymerase chain reaction for surrogate markers of fibrosis Col1 (P = 0.0083) and α-smooth muscle actin (P = 0.0349). There was an associated reduction in markers of the profibrotic alternative macrophage activation phenotype, Ym1 (P = 0.0179), and Arginase1. The alternative macrophage marker CD163 was expressed on lung macrophages from patients with IPF. Depletion of Ly6Chi circulating monocytes reduced pulmonary fibrosis (P = 0.0052) and the number of Ym1-positive alternatively activated lung macrophages (P = 0.0310). Their adoptive transfer during fibrogenesis exacerbated fibrosis (P = 0.0304); however, adoptively transferred CD45.1 Ly6Chi cells were not found in the lungs of recipient CD45.2 mice. Conclusions: We demonstrate the importance of circulating monocytes and lung macrophages during pulmonary fibrosis, and emphasize the importance of the alternatively activated macrophage phenotype. We show that Ly6Chi monocytes facilitate the progression of pulmonary fibrosis, but are not obviously engrafted into lungs thereafter. Finally, we provide empirical data to suggest that macrophages may have a resolution-promoting role during the reversible phase of bleomycin-induced pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“depletion of Mo-AMs via several strategies conferred protection from lung fibrosis in multiple mouse models1,3,10,11,13,20”
From TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity (2025) · cites this paper as [20]
In the citing paper
“it remains largely unclear what regulates their pro-fibrotic potency in the lung2,3,19–27”
From TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity (2025) · cites this paper as [20]
In the citing paper
“Although it has long been recognized that macrophages play a crucial role in the pathogenesis of lung fibrosis”
From TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity (2025) · cites this paper as [20]
In the citing paper
“removal (27, 28) or repolarizing (27) of interstitial macrophages is both preventative and therapeutic in several mouse models of IPF”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [28]
In the citing paper
“The importance of macrophages in regulating fibrosis is demonstrated by the observation that in mice, deletion of lung macrophages using liposomal chlodronate reduces bleomycin induced lung fibrosis, and a similar effect is obtained if circulating monocytes are depleted using liposomal chlodronate (169).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [169]
Citations
Cites
Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties
Geissmann, F., Jung, S., & Littman, D. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00174-2 · Cited by 3,391
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“A new hypothesis was developed in which aberrant wound healing was believed to be the more likely mechanism for disease development (9).”
BackgroundBlood Monocytes: Development, Heterogeneity, and Relationship with Dendritic Cells
Auffray, C., Sieweke, M. H., & Geissmann, F. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132557 · Cited by 1,655 · cited 1×
“Some authors suggest that in tissue, Ym1-positive macrophages are derived from Ly6C monocytes (49).”
BackgroundSelective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 2×
“This novel finding is in keeping with the role of macrophages during the resolution of liver fibrosis (16) and fits nicely with work showing that alveolar macrophages are involved in the removal of accumulated collagen (29), suggesting that macrophage manipulation for modulation of fibrosis may be possible.”
BackgroundResultSelf-citationCD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“The archetypal fibrotic lung disease, idiopathic pulmonary fibrosis (IPF), is a devastating disorder with an unknown natural history (1); there are no effective therapies (2), its incidence is rising (3), and it has a median survival of between 2.”
BackgroundCD4 + CD25 + Foxp3 + regulatory T cells induce alternative activation of human monocytes/macrophages
Tiemessen, M. M., Jagger, A. L., Evans, H. G., van Herwijnen, M. J. C., John, S., & Taams, L. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706832104 · Cited by 852 · cited 1×
“CD163, a human marker of alternative macrophage activation (31), was not expressed on lung macrophages from elderly healthy volunteers (Figure 4H), but importantly and in contrast, was shown to be expressed on greater than 90% of lung macrophages from patients with IPF (Figure 4I).”
BackgroundMurine models of pulmonary fibrosis
Moore, B. B., & Hogaboam, C. M. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00313.2007 · Cited by 796 · cited 1×
“Fibrosis begins to develop after 14 days and usually peaks after 21–28 days (22).”
BackgroundBroekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794 · cited 1×
“Interestingly, a study of patients with IPF using in situ hybridization demonstrated that TGFb1 mRNA was present in macrophages adjacent to fibroblastic foci, but that the foci themselves showed no signal for TGFb1 mRNA (51).”
Background
Research works printed but not linked: 2
- Gibbons, 2009, A critical role for alternatively activated monocytes and macrophages in the pathogenesis of pulmonary fibrosis [abstract], Thorax, 64, A37
- Gibbons, 2010, Ly6Chi circulating monocytes direct alternatively activated, pro-fibrotic, lung macrophage regulation of pulmonary fibrosis, Thorax, 65, A57
Cited by
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
Alveolar macrophages: plasticity in a tissue-specific context
Hussell, T., & Bell, T. J. (2014) · Nature Reviews Immunology · doi:10.1038/nri3600 · Cited by 1,377
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
Self-citationMonocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
Misharin, A. V., Morales-Nebreda, L., Reyfman, P. A., Cuda, C. M., Walter, J. M., McQuattie-Pimentel, A. C., Chen, C.-I., Anekalla, K. R., Joshi, N., Williams, K. J. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162152 · Cited by 1,133
“, using Ccr2−/− mice or via the systemic administration of liposomal clodronate) ameliorates fibrosis severity in the lung and other organs (Moore et al., 2001; Gibbons et al., 2011; Wynn and Vannella, 2016).”
BackgroundMethodResult
Metadata
- Authors
- Gibbons, M. A., MacKinnon, A. C., Ramachandran, P., Dhaliwal, K., Duffin, R., Phythian-Adams, A. T., van Rooijen, N., Haslett, C., Howie, S. E., Simpson, A. J., Hirani, N., Gauldie, J., Iredale, J. P., Sethi, T., & Forbes, S. J.
- Affiliations
- Royal Devon & Exeter NHS Foundation Trust (GB)
- Centre for Inflammation Research (GB)
- Institute of Immunology and Infection Research, and
- Department of Molecular Cell Biology, Vrije University, Amsterdam, The Netherlands
- Medical Research Council/University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh, United Kingdom
- McMaster University (CA)
- King's College London (GB)
- MRC Centre for Regenerative Medicine (GB)
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-01
- Volume
- 184
- Issue
- 5
- Pages
- 569-581
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2111920665
- Cited by
- 466
- References
- 50
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 32 · 2023: 34 · 2022: 38 · 2021: 38 · 2020: 30 · 2019: 37 · 2018: 31 · 2017: 34 · 2016: 38 · 2015: 23 · 2014: 24 · 2013: 30 · 2012: 15
- FWCI
- 19.59
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, pulmonary fibrosis, Ly6Chi monocytes, M2 macrophages, M2 macrophage polarization, Ym1, arginase-1, CD163, macrophage depletion, adoptive transfer, bleomycin-induced lung fibrosis, fibrosis resolution, collagen deposition
- MeSH terms
- Animals, Bleomycin, Disease Models, Animal, Female, Humans, Immunity, Cellular, Macrophage Activation, Monocytes, Phenotype, Pulmonary Fibrosis, Macrophages, Alveolar, Disease Progression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ly6Chi Monocytes Direct Alternatively Activated Profibrotic Macrophage Regulation of Lung Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201010-1719oc
- The paper
- Gibbons, M. A., MacKinnon, A. C., Ramachandran, P., Dhaliwal, K., Duffin, R., Phythian-Adams, A. T., van Rooijen, N., Haslett, C., Howie, S. E., Simpson, A. J., Hirani, N., Gauldie, J., Iredale, J. P., Sethi, T., & Forbes, S. J. (2011). Ly6Chi Monocytes Direct Alternatively Activated Profibrotic Macrophage Regulation of Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201010-1719oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.